

25 Aug 2024 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: CMS's price reveal better than expected?; new diabetes risk data for Zepbound; can J&J's lung cancer combo stand up to Tagrisso?; new recruits for BioMarin leadership; and Glenmark's shifting revenues.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 23 August 2024, including: CMS's price reveal better than expected?; new diabetes risk data for Zepbound; can J&J's lung cancer combo stand up to Tagrisso?; new recruits for [BioMarin Pharmaceutical Inc.](#) leadership; and [Glenmark Pharmaceuticals Limited](#)'s shifting revenues.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[CMS's Big Drug Price Reveal Turns Out Better For Pharma Than Feared](#)" - Scrip, 15 Aug, 2024.)

(Also see "[Lilly Data Show Zepbound Reduces Type 2 Diabetes Risk Long Term](#)" - Scrip, 20 Aug, 2024.)

(Also see "[Can J&J's Rybrevant/Lazcluze Combo Stand Up To Tagrisso?](#)" - Scrip, 20 Aug, 2024.)

(Also see "[BioMarin Recruits Amgen R&D's Friberg, Roche Dealmaker Sabry To Leadership Team](#)" - Scrip, 21 Aug, 2024.)

(Also see "[Glenmark Chief On 'Big Shift' In Revenue By Region, Liraglutide India Outlook](#)" - Scrip, 21 Aug, 2024.)

[Click here to explore this interactive content online](#) ✨